A NEW weight loss drug may offer a tempting alternative to popular GLP-1 drugs like Ozempic and Wegovy. The once-weekly injection has been shown to be as effective as Mounjaro – but patients

Trial participants who used eloralintide, a new weight loss medication that, instead of focusing on the hormone GLP-1, targets a different hormone called amylin, lost as much as 20% weight.

Biotech companies are racing to find Ozempic 2.0, hoping for a slice of a multi-billion-dollar industry. A few stand-out drugs are emerging.

A WEIGHT loss pill set to be available next year will be a cheaper, easier and effective alternative to Mounjaro injections, say experts. They hope orforglipron will “open the door to treatment

The daily pill may provide a more convenient alternative to injections, which patients can find difficult to administer.

A major new clinical trial involving more than 1,600 people has found that a GLP-1 pill form of the drug orforglipron works about as well as injectable semaglutide for people with type 2 diabetes. Following an experiment conducted over 72 weeks and across 136 sites in 10 countries,

Danish drugmaker Novo Nordisk A/S was at the forefront of the weight-loss injection boom as people discovered that its Ozempic shot, originally developed to treat diabetes, could help trim their waistlines.

GLP-1 drugs like tirzepatide and semaglutide offer powerful weight-loss effects but come with unanswered questions about long-term safety, side effects, and global accessibility. Researchers stress the need for independent studies before these treatments can be fully embraced worldwide.

This article was reviewed by Craig Primack, MD, FACP, FAAP, FOMA. Weight loss can be a challenge, even for those who eat healthily and exercise regularly. Injectable weight loss medications — also known as GLP-1 and GIP injections — can help when ...

Researchers found benefits including reduced blood pressure were reversed after patients ceased taking the jab

Orforglipron, new GLP-1 weight loss pill dubbed cheaper and more convenient than the jabs could be on the market soon